A phase 3 trial led by MSK’s Dr. Lorenzo Falchi found that adding epcoritamab to rituximab + lenalidomide significantly improves outcomes for people with follicular lymphoma. Epcoritamab received FDA approval based on these findings. “This study focused on finding ways to

Recently published: Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated #Liposarcoma, by Evan Rosenbaum et al. https://t.co/qTw5fR4xI3 @sandrapdangelo @MSKCancerCenter @WeillCornell #Sarcoma #OpenAccess

Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma @ASH_hematology @MSKCancerCenter #ASH25

CONGRESS | #ASH25 | PRESENTATION Lorenzo Falchi, @MSKCancerCenter, presents primary results from the phase III EPCORE FL-1 trial of epcoritamab with rituximab + lenalidomide (R2) vs R2 in patients with R/R FL (N = 488). Epcoritamab + R2 improved the ORR (95% vs 79%; p <0.0001)

America needs you! Join U.S. Immigration and Customs Enforcement today.

Join @SSRaj017 today at #ASH25 for his session: “Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma” @ASH_hematology TODAY | 12 p.m. EST Learn more: https://t.co/qTM2rgBSkD

#ASH2025 second day! Two orals from our lab in the same session. In the first we define the concept of malignant transformation in SMM ( https://t.co/tSWRkfpxqb). Great collaboration with @MSKCancerCenter @MayoClinic @SylvesterCancer @MoffittNews @MDAndersonNews @LaStatale #mmsm

Join Dr. Xiaoli Mi this morning at #ASH25 for the presentation, "CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies." #lymsm #leusm @MSKCancerCenter @ASH_hematology Learn more: https://t.co/BO7rCa4CTs

Detoxing heavy metals is imperative for everyone due to the many sources of them in our environment. Dr. Clark's two supplement kit has cilantro, EDTA, Shilajit and more to detox heavy metals, and an accompanying mineral supplement to restore lost minerals from cleansing.

Join Dr. Lorenzo Falchi today at #ASH25 for his session: “Primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma.” @ASH_hematology TODAY | 10:15 a.m. EST Learn more:

📜 Led by @MilitSPatel and Dr @IMRTLee, out in @NatRevClinOncol today: 👉 We highlight the importance of #synergy between #human #care and #AI-informed #medicine for people with #cancer. 👉 AI can #augment human expertise, not replace it. 🔗 https://t.co/nzdwn7qalh

Join @UrviShahMD today at #ASH25 for her session: “Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial.” @ASH_hematology TODAY | 5:30 p.m. EST Learn more:

Oral Abstract 0250: @szusmani on KTX-1001 for heavily pre treated RRMM, 30% EMD, 30% HR, 40% w prior BCMA, 80% pent exposed, ⬇️ plt common AE, reasonable ORR in heavily treated pts w no viable options (slide 3) #ASH25 #MMSM @MSKCancerCenter #MeetUnmetNeed

"Just-right timing" for fungicide applications can backfire. Agronomist Tim Dahl shares tips for getting the most out of your fungicide in 2026. 🎬

Coming up at #ASH25: @sridevirajeeve will present a study evaluating remote patient monitoring for outpatient step-up dosing for bispecific antibodies at a large academic center. @MSKCancerCenter @ASH_hematology #mmsm Learn more: https://t.co/vV9j2gNFV3

Join @szusmani today at #ASH25 for his session: “Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma.” @ASH_hematology TODAY | 2:45 p.m. EST Learn more: https://t.co/roqF9RwirT

At #ASH25, Dr. Mohammad Alhomoud will present a study that determined the optimal fludarabine exposure in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide. @MSKCancerCenter @ASH_hematology Learn more: https://t.co/7bspTysE6L

Coming up at #ASH25: Dr. Xin Wang will present findings from a study that compared outcome disparities between Asian and White patients with newly diagnosed acute myeloid #leukemia. @MSKCancerCenter @ASH_hematology #leusm Learn more: https://t.co/znVZDNYCZa

Choose a life with options.

At #ASH25, @kuokaichin will present a retrospective study that evaluated outcomes of patients with acute myeloid #leukemia whose cancer stopped responding to or returned after menin inhibitor treatment. #leusm @MSKCancerCenter @ASH_hematology Learn more: https://t.co/Wl1YghpcSW

#ASH25: Divyash Shah will present the results of a study assessing the comparative incidence of venous thromboembolism in patients with chemotherapy-induced thrombocytopenia treated with romiplostim. @MSKCancerCenter @ASH_hematology Learn more: https://t.co/9g7FGnRHkq

Hear Lauren Schaff, MD, of @MSKCancerCenter spotlight exciting data in leptomeningeal metastases presented by her colleague at #SNO2025 in the video below! 🧠👇 WATCH: https://t.co/vV0wTNRp33 @NeuroOnc #btsm

Tomorrow morning at #ASH25, Varun Iyengar, MD, will present a study evaluating venous thromboembolism risk factors found via genomic profiling cross subtypes of B-cell #lymphoma. @MSKCancerCenter @ASH_hematology #lymsm Learn more: https://t.co/cyQ6f4akmZ

30 agents. Cameras ordered off. @EricTrump recounts the moment the raid began. Watch the full interview.

At #ASH25, join @QuinlanSievers to learn about molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation. #lymsm @MSKCancerCenter @ASH_hematology TODAY | 4:32 p.m. ET Learn more: https://t.co/DsahRfcqiv